Wells Fargo raised the firm’s price target on Cencora to $249 from $236 and keeps an Equal Weight rating on the shares. The firm says results in Q3 were solid, with upside vs. consensus in U.S. Healthcare as Cencora continues to generate growth solidly above LRP levels. The company raised fiscal 2024 EPS guidance by 1.5%, Wells adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: